Covid-19 Rapid Test
CE-Marked Point-of-Care Real-Time PCR Diagnostics
Our SARS-CoV-2 (COVID-19) rapid test is a CE marked real time PCR cartridge, providing clear and concise results in a timely manner, direct at the point of care. This enables individuals to take the recommended safety precautions without delay. The SARS-CoV-2 rapid test targets the E gene sequence for COVID-19 detection in just 39 minutes with minimal workflow required, suitable for laboratory and non-laboratory settings.
Detection Method: Real-Time PCR
Result Time: 39 Minutes
Sample Volume: 300μl Clinical Sample
Sample Type: Nasopharyngeal or Oropharyngeal Swab
Vivalytic cartridge-based platform
The new SARS-CoV-2 rapid test will be conducted on Vivalytic, a point of care platform brought to the market by Randox Laboratories and Bosch.
The Vivalytic system is a fully-automated, cartridge-based platform capable of both Hi-Plex and Lo-Plex infectious disease testing. Each easy to use cartridge contains all necessary reagents, is fully-sealed to minimise risk and can be conveniently stored at room temperature.
Vivalytic Key Features:
- Cartridge based platform
- Suitable for both non-laboratory & laboratory settings
- Small footprint device
- Rapid turnaround from sample entry to results
- Available as stand-alone or modular with up to 8 platforms
Acusera Independent Quality Control for SARS-CoV-2 Serology Assays
Comprising both reactive and non-reactive controls for Anti SARS-CoV-2 , the Acusera SARS-CoV-2 Antibody Control will support assay validation and routine performance monitoring of serological assays for COVID-19. Conveniently supplied in a liquid ready-to-use format with a 30 day open vial stability, waste is kept to a minimum. As a true third party control, independent performance assessment is guaranteed.
- Liquid ready-to-use requiring no preparation
- 100% human plasma providing a matrix similar to the patient sample
- True third party control ensuring unbiased performance assessment
- Reactive and non-reactive controls available
- Open vial stability of 30 days at 2ºC to 8ºC
- Suitable for use with Anti SARS-CoV-2 assays
Molecular Controls for Infectious Disease
New Respiratory Target Multiplex (RTX) Controls
The Qnostics RTX control range enables the requirements for testing strategies during the upcoming flu season to be met. The range covers the viral and bacterial pathogens responsible for an array of respiratory diseases in various patient cohorts, whilst discriminating cold and flu from COVID-19.
RTX Plus Q Control
Target Pathogen – Influenza A (H1N1), Influenza B (Victoria), RSV A, Coronavirus (SARS-CoV-2)
RTX2 Q Control
Target Pathogen – Parainfluenza 1, Adenovirus 1, Mycoplasma pneumoniae, Coronavirus (OC43)
RTX3 Q Control
Target Pathogen – Parainfluenza 2, Metapneumovirus (A2), Enterovirus (A16), Coronavirus (229E)
RTX4 Q Control
Target Pathogen – Parainfluenza 3, Rhinovirus (16), Legionella pneumophila, Coronavirus (NL63)
RTX5 Q Control for paediatric testing.
Target Pathogen – Parainfluenza 4, Adenovirus (14), RSV B, Enterovirus (D68)
Independent Third-Party Serology Controls for Accurate and Reliable Results
Randox Infectious Disease Serology Controls
User-friendly: Liquid ready-to-use and multi-analyte based, reducing the number of different control tubes in the lab
High quality: Human plasma-based with clinically relevant measuring values, manufactured under strict conditions
Economical: 60 day open vial stability for reduced waste
Lyme Disease: positive and negative, IgG and IgM
ToRCH: IgG positive, IgM positive, negative
Epstein Barr Virus, EBV: positive
Sample to Answer Molecular Diagnostics
Respiratory Virus Detection using Point of Care Technology
The Vivalytic Molecular Panels are expanding:
SARS-CoV-2 2-plex test for detection of the E-gene and Rdrp-gene
Viral Respiratory Tract Infection Array for 10 viral respiratory infections, including SARS-CoV-2
SARS-CoV-2 1-plex for detection of E-gene
The automated workflow covers all steps and take place in the dedicated cartridge, for maximal user convenience and reliable results.
Extended Molecular Coronavirus Array
Evidence Investigator Semi-automated Compact Benchtop System without Compromising on the Volume of Samples Processed
The Molecular Coronavirus Array simultaneously detects five strains of coronavirus including the COVID-19 (SARS-CoV-2, 229E, NL63, OC43 and HKU1). The wider panel provides a more comprehensive respiratory screen enabling informed treatment decisions to be made.
The new test utilises Randox Biochip Technology, with results available for 54 patient samples in less than 5 hours.
Sample Volume Investigator: 5μl of Nucleic Acid required for PCR detection.
Reduce the Number of False Negatives in SARS-CoV-2 Detection
New 4X 1Step RT-qPCR Kit for Detection of <5 Copies per Reaction
- Successfully tested for SARS Co-V-2 Diagnostics
- Ideal for multi-plex protocols
- Reliable outcome in single-step RT-qPCR for low copy number detection
- Robust 4x 1-step mastermix including a hotstart PCR polymerase, an extremely active reverse transcriptase, advanced RNAse inhibitor and PCR water
- Compatible with all commonly used instrument platforms
Develop and Validate Detection Assays with Positive SARS-CoV-2 Control
Complete SARS-CoV-2 Transcriptome in RNA Fragments
Game-Changing Test with Point of Care System
Molecular Infectious Disease Testing
Kit-Independent, Third Party Controls
Qnostics controls from Randox Laboratories are independent 3rd party controls, specifically designed for molecular nucleic acid detection in infectious medicine testing.
Controls are based on whole pathogens, and designed to fully reflect the detection of patient samples.
You are able to assess the entire testing process from extraction though amplification and detection.
Easy-to-use; delivered in a liquid frozen format.
Manufactured to ISO 13485 quality standards.
The following disease areas are covered:
Transplantation Associated Disease
Respiratory Infections Testing
Blood Borne Virus Testing
Sexually Transmitted Disease
Emergency Drugs of Abuse Screening with Multiplex Technology
Evidence Multistat is an automated benchtop immunoanalyser, using multiplex technology to enable more data from a single sample.
Simultaneous detection of 21 classical, prescription and synthetic drugs in one single sample
Easy to operate; analytes are prefilled in ready-to-use cartridges
High quality data with well tested Biochip Array technology
Speed: 21 analytes are analysed in 20 min
Save samples: only 200 ul required for analysis
The Importance of 3rd Party Quality Controls in Clinical Analysis
Why Use Control Reagents from an Independent Manufacturer?
Randox true third party controls are manufactured independently from reagents and calibrators. The unique value assignment process employs thousands of independent laboratories ensuring statistically valid targets are available for multiple instruments and methods.
With a shelf life of up to four years, laboratories can ensure continuity of lot supply whilst enabling long term QC monitoring. The availability of multi-analyte, multi-instrument controls will reduce costs and preparation time, consolidating multiple instrument specific controls into a single control product.